Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model

Journal of Ethnopharmacology

Volumn 124, Issue 1, 2009, Pages 103-110

  Chen, Wen Qiang ^a   Zhong, Lin ^b   Zhang, Lei ^a   Ji, Xiao Ping ^a   Zhao, Yu Xia ^a   Zhang, Cheng ^a   Jiang, Hong ^a   Wu, Yi Ling ^c   Zhang, Yun ^a  

^a BEIJING HOSPITAL   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c Institute of Integrated Traditional Chinese and Western Medicine Research   (China)

Author keywords

Inflammation; Simvastatin; Tongxinluo capsule; Vulnerable plaque

Indexed keywords

CHINESE DRUG; LIPID; SIMVASTATIN; TONGXINLUO; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHINESE MEDICINE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CAPSULE; ECHOGRAPHY; ENDOTHELIUM INJURY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIPID BLOOD LEVEL; NONHUMAN; RABBIT; SEROLOGY;

AMINOGLYCOSIDES; ANGIOSPERMS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; AORTA, ABDOMINAL; CHOLESTEROL; CHOLESTEROL, LDL; DIET; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; ENDOTHELIUM, VASCULAR; RABBITS; RANDOM ALLOCATION; SIMVASTATIN; TRIGLYCERIDES; TUNICA INTIMA;

ANGINA; ORYCTOLAGUS CUNICULUS;

EID: 67349244318     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2009.04.009     Document Type: Article

References (24)

1. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., and Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 (1998) 2433-2444
2. Armstrong E.J., Morrow D.A., and Sabatine M.S. Inflammatory biomarkers in acute coronary syndromes. Part I: Introduction and cytokines. Circulation 113 (2006) e72-e75
3. Carr S.C., Farb A., Pearce W.H., Virmani R., and Yao J.S. Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery 122 (1997) 757-763
4. Chen W.Q., Zhang L., Liu Y.F., Chen L., Ji X.P., Zhang M., Zhao Y.X., Yao G.H., Zhang C., Wang X.L., and Zhang Y. Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers. American Journal of Physiology-Heart Circulatory Physiology 293 (2007) H2836-H2844
5. Ding S.J., and Li J.S. Anti-oxidant effects of Tongxinluo on ATPase in focal brain ischemia-reperfusion rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chin) 31 (2006) 552-555
6. Hernández-Presa M.A., Ortego M., Tuñón J., Martín-Ventura J.L., Mas S., Blanco-Colio L.M., Aparicio C., Ortega L., Gómez-Gerique J., Vivanco F., and Egido J. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovascular Research 57 (2003) 168-177
7. Kong Q., Yang X.C., and Liu X.L. Effects of tongxinluo on the myocardial inflammatory reaction and expression of tumor necrosis factor-alpha in rats with myocardial infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi (Chin) 26 (2006) 545-549
8. Li Z., Yang Y.J., Qin X.W., Luan Y.M., Chen X., Meng L., and Zhang H.D. Effects of Tongxinluo and Simvastatin on the stabilization of vulnerable atherosclerotic plaques of aorta in aortic atherosclerosis and molecular mechanism thereof: a comparative study with rabbits. Zhonghua Yi Xue Za Zhi (Chin) 86 (2006) 3146-3150
9. Libby P., and Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nature Medicine 8 (2002) 1257-1262
10. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25 (2001) 402-408
11. Mintz G.S., Nissen S.E., Anderson W.D., Rosenfield K., Bailey S., Siegel R., Erbel R., Tuzcu E.M., Fitzgerald P., Yock P.G., and Pinto F.G. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, measurement and reporting of intravascular Ultrasound Studies (IVUS). Journal of American College of Cardiology 37 (2001) 1478-1492
12. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J., Badimon J.J., Stefanadis C., Moreno P., Pasterkamp G., Fayad Z., Stone P.H., Waxman S., Raggi P., Madjid M., Zarrabi A., Burke A., Yuan C., Fitzgerald P.J., Siscovick D.S., de Korte C.L., Aikawa M., Juhani Airaksinen K.E., Assmann G., Becker C.R., Chesebro J.H., Farb A., Galis Z.S., Jackson C., Jang I.K., Koenig W., Lodder R.A., March K., Demirovic J., Navab M., Priori S.G., Rekhter M.D., Bahr R., Grundy S.M., Mehran R., Colombo A., Boerwinkle E., Ballantyne C., Insull Jr. W., Schwartz R.S., Vogel R., Serruys P.W., Hansson G.K., Faxon D.P., Kaul S., Drexler H., Greenland P., Muller J.E., Virmani R., Ridker P.M., Zipes D.P., Shah P.K., and Willerson J.T. From vulnerable plaque to vulnerable patient. A call for new definition and risk assessment strategies: part I. Circulation 108 (2003) 1664-1772
13. National Pharmacopoeia Committee. Pharmacopoeia of China. 1st Part (2005), Chinese Publishing Company of Chemical Industry, Beijing pp. 17-22
14. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine 352 (2005) 20-28
15. Torzewski M., Klouche M., Hock J., Messner M., Dorweiler B., Torzewski J., Gabbert H.E., and Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arteriosclerosis Thrombosis and Vascular Biology 18 (1998) 369-378
16. Wang H.J., Xie L.D., Yao E.H., and Xu C.S. Effect of Tongxinluo on myocardial fibrosis in spontaneously hypertensive rats. Chinese Journal of Integrated Medicine of Cardiology/Cerebrovascular Disease (Chin) 1 (2003) 189-190
17. Wang W.J., Fu X.D., Chen W.H., Ying J., and Wang S.H. The experiment research of angiogenesis of Tongxinluo capsule on the chick embryo chorioallantoic membrane model. Chinese Journal Difficult and Complicated Cases (Chin) 2 (2003) 2-4
18. Williams H., Johnson J.L., Carson K.G., and Jackson C.L. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arteriosclerosis Thrombosis and Vascular Biology 22 (2002) 779-788
19. Wiviott S.D., de Lemos J.A., Cannon C.P., Blazing M., Murphy S.A., McCabe C.H., Califf R., and Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 113 (2006) 1406-1414
20. Wu T., Harrison R.A., Chen X., Ni J., Zhou L., Qiao J., Wang Q., Wei J., Xin D., and Zheng J. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. Cochrane Database Systemic Review 18 (2006) CD004474
21. Wu Y.L., You J.H., Yuan G.Q., Liang J.Q., Jia Z.H., Liu K.J., and Wei C. The effects of Tongxinluo Supermicro Powder on nuclear factor-kappaB, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in aorta of rabbits fed with high-lipid diet. Zhonghua Xin Xue Guan Bing Za Zhi (Chin) 35 (2007) 271-274
22. Xu X.L., Zhang Z.R., and Huang Y. Optimization of the separation conditions of fingerprint for rhubarb by high performance liquid chromatography. Sichuan Da Xue Xue Bao Yi Xue Ban (Chin) 35 (2004) 559-562
23. Zhang Y.H., Ji M., Zhang Y.L., and Wang X.Y. Effects of Tongxinluo capsule on endothelial function of patients with dysfunction of blood lipid profile. Chinese Journal Difficult and Complicated Cases (Chin) 4 (2005) 92-93
24. Zhao M.Z., Gao C.M., Zhang Y.Y., and Wang J.R. Effects of Tongxinluo capsule on myocardial apoptosis and apoptosis-related gene expression after ischaemi-reperfusion. Chinese Journal of Cardiology (Chin) 28 (2000) 206